185 related articles for article (PubMed ID: 25332877)
1. Effects of de-escalated bisphosphonate therapy on bone turnover biomarkers in breast cancer patients with bone metastases.
Addison CL; Pond GR; Zhao H; Mazzarello S; Vandermeer L; Goldstein R; Amir E; Clemons M
Springerplus; 2014; 3():577. PubMed ID: 25332877
[TBL] [Abstract][Full Text] [Related]
2. A phase II, multicentre trial evaluating the efficacy of de-escalated bisphosphonate therapy in metastatic breast cancer patients at low-risk of skeletal-related events.
Addison CL; Bouganim N; Hilton J; Vandermeer L; Dent S; Amir E; Hopkins S; Kuchuk I; Segal R; Song X; Gertler S; Mazzarello S; Dranitsaris G; Ooi D; Pond G; Clemons M
Breast Cancer Res Treat; 2014 Apr; 144(3):615-24. PubMed ID: 24638849
[TBL] [Abstract][Full Text] [Related]
3. Randomized feasibility study of de-escalated (every 12 wk) versus standard (every 3 to 4 wk) intravenous pamidronate in women with low-risk bone metastases from breast cancer.
Amir E; Freedman O; Carlsson L; Dranitsaris G; Tomlinson G; Laupacis A; Tannock IF; Clemons M
Am J Clin Oncol; 2013 Oct; 36(5):436-42. PubMed ID: 22781385
[TBL] [Abstract][Full Text] [Related]
4. Effects on bone resorption markers of continuing pamidronate or switching to zoledronic acid in patients with high risk bone metastases from breast cancer.
Hilton JF; Clemons M; Pond G; Zhao H; Mazzarello S; Vandermeer L; Addison CL
J Bone Oncol; 2018 Mar; 10():6-13. PubMed ID: 29204337
[TBL] [Abstract][Full Text] [Related]
5. Should de-escalation of bone-targeting agents be standard of care for patients with bone metastases from breast cancer? A systematic review and meta-analysis.
Ibrahim MF; Mazzarello S; Shorr R; Vandermeer L; Jacobs C; Hilton J; Hutton B; Clemons M
Ann Oncol; 2015 Nov; 26(11):2205-13. PubMed ID: 26122727
[TBL] [Abstract][Full Text] [Related]
6. Correlation of baseline biomarkers with clinical outcomes and response to fulvestrant with vandetanib or placebo in patients with bone predominant metastatic breast cancer: An OCOG ZAMBONEY sub-study.
Addison CL; Pond GR; Cochrane B; Zhao H; Chia SK; Levine MN; Clemons M
J Bone Oncol; 2015 Jun; 4(2):47-53. PubMed ID: 26579488
[TBL] [Abstract][Full Text] [Related]
7. Effects of de-escalated bisphosphonate therapy on the Functional Assessment of Cancer Therapy-Bone Pain, Brief Pain Inventory and bone biomarkers.
Kuchuk I; Beaumont JL; Clemons M; Amir E; Addison CL; Cella D
J Bone Oncol; 2013 Dec; 2(4):154-7. PubMed ID: 26909286
[TBL] [Abstract][Full Text] [Related]
8. De-escalation of bone-modifying agents in patients with bone metastases from breast cancer: a systematic review and meta-analysis.
Awan AA; Hutton B; Hilton J; Mazzarello S; Van Poznak C; Vandermeer L; Bota B; Stober C; Sienkiewicz M; Fergusson D; Shorr R; Clemons M
Breast Cancer Res Treat; 2019 Aug; 176(3):507-517. PubMed ID: 31079283
[TBL] [Abstract][Full Text] [Related]
9. Is De-escalated Bisphosphonates Therapy a Suitable Alternative to Standard Dosing in Malignant Tumor Patients With Bone Metastases: A Systematic Review and Meta-Analysis.
Luo Q; Men P; Liu Z; Zhai S; Jiang M
Front Oncol; 2019; 9():774. PubMed ID: 31475116
[No Abstract] [Full Text] [Related]
10. Bisphosphonates for breast cancer.
Pavlakis N; Schmidt R; Stockler M
Cochrane Database Syst Rev; 2005 Jul; (3):CD003474. PubMed ID: 16034900
[TBL] [Abstract][Full Text] [Related]
11. Bisphosphonates and other bone agents for breast cancer.
Wong MH; Stockler MR; Pavlakis N
Cochrane Database Syst Rev; 2012 Feb; (2):CD003474. PubMed ID: 22336790
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of de-escalation bone- modifying agents for cancer patients with bone metastases: a systematic review and meta-analysis.
Liu C; Wang L; Liu L; Zhuang J; Tang S; Zhang T; Zhou C; Feng F; Liu R; Zhang J; Zhang T; Gao C; Li H; Li J; Sun C
Cancer Manag Res; 2018; 10():3809-3823. PubMed ID: 30288112
[TBL] [Abstract][Full Text] [Related]
13. A Phase II trial evaluating the palliative benefit of second-line oral ibandronate in breast cancer patients with either a skeletal related event (SRE) or progressive bone metastases (BM) despite standard bisphosphonate (BP) therapy.
Clemons M; Dranitsaris G; Ooi W; Cole DE
Breast Cancer Res Treat; 2008 Mar; 108(1):79-85. PubMed ID: 17473981
[TBL] [Abstract][Full Text] [Related]
14. Skeletal-related events (SREs) in breast cancer patients with bone metastases treated in the nontrial setting.
Trinkaus M; Simmons C; Myers J; Dranatisaris G; Clemons M
Support Care Cancer; 2010 Feb; 18(2):197-203. PubMed ID: 19424729
[TBL] [Abstract][Full Text] [Related]
15. Bisphosphonates for breast cancer.
Pavlakis N; Stockler M
Cochrane Database Syst Rev; 2002; (1):CD003474. PubMed ID: 11869664
[TBL] [Abstract][Full Text] [Related]
16. Use of bisphosphonates in metastatic breast cancer: single institution review at the Dr. H. Bliss Murphy Cancer Centre.
Murphy L; McCarthy J; McCrate F; Laing K; Powell E; Seal M; Edwards S
Support Care Cancer; 2013 Jun; 21(6):1557-60. PubMed ID: 23334521
[TBL] [Abstract][Full Text] [Related]
17. The new bisphosphonate, Zometa (zoledronic acid), decreases skeletal complications in both osteolytic and osteoblastic lesions: a comparison to pamidronate.
Lipton A; Small E; Saad F; Gleason D; Gordon D; Smith M; Rosen L; Kowalski MO; Reitsma D; Seaman J
Cancer Invest; 2002; 20 Suppl 2():45-54. PubMed ID: 12442349
[TBL] [Abstract][Full Text] [Related]
18. A systematic review of dosing frequency with bone-targeted agents for patients with bone metastases from breast cancer.
Hutton B; Addison CL; Campbell K; Fergusson D; Mazarello S; Clemons M
J Bone Oncol; 2013 Sep; 2(3):123-31. PubMed ID: 26909282
[TBL] [Abstract][Full Text] [Related]
19. The ZOTECT study: Effect of zoledronic acid on bone metabolism in patients with bone metastases from prostate or breast cancer.
Hadji P; Ziller M; Maurer T; Autenrieth M; Muth M; Ruebel A; May C; Birkholz K; Diebel E; Gleissner J; Rothe P; Gschwend JE
J Bone Oncol; 2012 Dec; 1(3):88-94. PubMed ID: 26909262
[TBL] [Abstract][Full Text] [Related]
20. A randomized, double-blind, phase II, exploratory trial evaluating the palliative benefit of either continuing pamidronate or switching to zoledronic acid in patients with high-risk bone metastases from breast cancer.
Jacobs C; Kuchuk I; Bouganim N; Smith S; Mazzarello S; Vandermeer L; Dranitsaris G; Dent S; Gertler S; Verma S; Song X; Simos S; Cella D; Clemons M
Breast Cancer Res Treat; 2016 Jan; 155(1):77-84. PubMed ID: 26643085
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
